The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.

The instant invention provides near-infrared fluorescent biological contrast agents and methods of using them.

The present invention provides a compound of formula (I): A-B-C (I), wherein A is a hydrophobic moiety; B is a peptide, wherein the peptide forms a beta-sheet; and C is a hydrophilic targeting ligand, wherein the hydrophilic targeting ligand is a LLP2A prodrug, LLP2A, LXY30, LXW64, DUPA, folate, a LHRH peptide, a HER2 ligand, an EGFR ligand, or a toll-like receptor agonist CpG oligonucleotides. The present invention also provides nanocarriers comprising compounds of the present invention, nanofibril formation from the nanocarriers, and methods of using the nanocarriers for treating diseases and imaging.

The present disclosure relates to a novel compound having an antibacterial function against superbacteria and a hypochlorous acid selective detection function, and a composition and a fluorescent sensor which comprise the same, and more particularly to, a novel imidazoline-2-thione based compound, a composition comprising the same, and a fluorescent sensor for bacterial detection and hypochlorous acid selective detection.

The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.

Described herein are new silicone-based compounds that have short wavelength infrared (SWIR) absorption and emission. The silicone-based compounds are readily accessible and obtainable on large scale with high purity through simple purification procedures. In one aspect, the silicone-based compounds have an absorption extending into the SWIR region and an emission maximum in the SWIR region which is promising for biological imaging applications.

The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Trypan Blue ophthalmic solutions are used to create and identify a landmark on the anterior capsule of an eye and thus identify a preferred location for an anterior capsulotomy during cataract surgery.

Described herein are compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, isotopically labeled derivatives and radiolabeled derivative thereof, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for detecting and imaging Tau aggregates in the brain for detection of Alzheimer's disease (AD) in a subject.